Evidence map›Paper›PMID 25788277›Full record

ArticleOncotarget2015

HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients.

Vaishali Pannu, Padmashree C G Rida, Angela Ogden, Ravi Chakra Turaga, Shashikiran Donthamsetty, Nathan J Bowen, Katie Rudd, Meenakshi V Gupta, Michelle D Reid, Guilherme Cantuaria and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Microtubule regulation in cancer cells.Frontiers in cell and developmental biology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. High KIFC1 expression is associated with poor prognosis in prostate cancer.Medical oncology (Northwood, London, England) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Vaishali PannuDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Padmashree C G RidaDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Angela OgdenDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Ravi Chakra TuragaDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Shashikiran DonthamsettyDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Nathan J BowenCenter for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USA.
Katie RuddDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
Meenakshi V GuptaClinical Pathology & Anatomic Pathology, West Georgia Hospitals, LaGrange, GA, USA.
Michelle D ReidDepartment of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Guilherme CantuariaDepartment of Gynecologic Oncology, Northside Hospital Cancer Institute, Atlanta, GA, USA.
Claire E WalczakDepartment of Medical Sciences, Indiana University, Bloomington, IN, USA.
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA, USA.
Georgia State University · USEmory University · USClark Atlanta University · USIndiana University Bloomington · USNorthside Hospital · US

Funding

Technologies/Resources for Core LaboratoriesG12MD007590 · NIMHD · CLARK ATLANTA UNIVERSITY · PI KHAN, SHAFIQ A · 2012 to 2018
$7.6M
Mechanisms of Spindle AssemblyR01GM059618 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI WALCZAK, CLAIRE E · 1999 to 2016
$4.7M
Evaluation of HSET as a Novel Theranostic Target for Breast Cancer TherapyR01CA169127 · NCI · GEORGIA STATE UNIVERSITY · PI ANEJA, RITU · 2012 to 2016
$1.7M
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggrU01CA179671 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA169127NCI NIH HHS U01 CA179671NIGMS NIH HHS R01 GM059618NIMHD NIH HHS G12 MD007590
6 · The paper itself

Abstract

Human breast tumors harbor supernumerary centrosomes in almost 80% of tumor cells. Although amplified centrosomes compromise cell viability via multipolar spindles resulting in death-inducing aneuploidy, cancer cells tend to cluster extra centrosomes during mitosis. As a result cancer cells display bipolar spindle phenotypes to maintain a tolerable level of aneuploidy, an edge to their survival. HSET/KifC1, a kinesin-like minus-end directed microtubule motor has recently found fame as a crucial centrosome clustering molecule. Here we show that HSET promotes tumor progression via mechanisms independent of centrosome clustering. We found that HSET is overexpressed in breast carcinomas wherein nuclear HSET accumulation correlated with histological grade and predicted poor progression-free and overall survival. In addition, deregulated HSET protein expression was associated with gene amplification and/or translocation. Our data provide compelling evidence that HSET overexpression is pro-proliferative, promotes clonogenic-survival and enhances cell-cycle kinetics through G2 and M-phases. Importantly, HSET co-immunoprecipitates with survivin, and its overexpression protects survivin from proteasome-mediated degradation, resulting in its increased steady-state levels. We provide the first evidence of centrosome clustering-independent activities of HSET that fuel tumor progression and firmly establish that HSET can serve both as a potential prognostic biomarker and as a valuable cancer-selective therapeutic target.

Indexed as

AneuploidyBiomarkers, TumorBreast NeoplasmsCell Line, TumorCentrosomeDisease ProgressionFemaleHeLa CellsHumansInhibitor of Apoptosis ProteinsKinesinsMicrotubulesNeoplasm GradingSurvivinTransfectionUp-RegulationBiomarkers, TumorBIRC5 protein, humanInhibitor of Apoptosis ProteinsKIFC1 protein, humanKinesinsSurvivincell-cycle kineticscentrosome clusteringHSETmicrotubule motortumor progression

Identifiers

PMID25788277
PMCPMC4467423
OpenAlexW2133388973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.